Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Medicaid Coverage of and Spending on GLP-1s GLP-1 (glucagon-like peptide-1) drugs were originally developed to help people with type 2 diabetes manage blood sugar levels but have gained widespread attention for their effectiveness as a treatment for obesity
In the STEP 1 trial, patients receiving semaglutide 2.4 mg with lifestyle support lost an average of 14.9% of their starting body weight over 68 weeks
Supporting digestive health during GLP-1 therapy can reduce electrolyte losses at the source
Many patients experience appetite suppression during tirzepatide therapy, particularly during the initial weeks of treatment and following dose escalations
Situations requiring healthcare provider consultation: Frequent dose timing inconsistencies that suggest adherence challenges Concurrent illness affecting medication absorption or tolerance Addition of new medications that may interact with tirzepatide Persistent or worsening gastrointestinal symptoms Any uncertainty about appropriate dose timing Patients should be aware that tirzepatide may reduce the effectiveness of oral hormonal contraceptives due to delayed gastric emptying
Some analysts forecast the market for diabetes cum weight-loss drugs, currently led by Novo Nordisk and Eli Lilly, could reach US$100 billion a year by the end of the decade.
US$ 28.18
US$ 20.49
US$ 20.72
US$ 23.67
US$ 25.80
US$ 26.76
